MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

References

• Edelman R. An overview of adjuvant use. In: Vaccine adjuvants: Preparation Methods and Researrh Protocols. OHagan D (Ed.). Humana Press, NJ, USA, 1–27 (2000).
   Google Scholar
• •Overview of adjuvant use.
   Google Scholar
• Ott G, Radhakrishnan R, Fang JH, Hora M. The adjuvant MF59: a 10-year perspective. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. OHagan D (Ed.). Humana Press, NJ, USA, 211–228 (2000).
   Google Scholar
• Dupuis M, Murphy TJ, Higgins D et al Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186,18–27 (1998).
   PubMed Web of Science ®Google Scholar
• Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18,434–439 (2000).
   Google Scholar
• ••Mechanism of action of MF59.
   Google Scholar
• Valensi JPM, Carlson JR, van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. immund 153, 4029–4039 (1994).
   Google Scholar
• Higgins DA, Carlson JR, van Nest G. MF59 enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14,478–484 (1996).
   Google Scholar
• Cataldo DM, van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15,1710–1715 (1997).
   PubMed Web of Science ®Google Scholar
• Traquina P, Morandi M, Contomi M, van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. Infect. Dis. 174,1168-1175 (1996).
   Google Scholar
• Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Nat! Acad. Sci. USA 91,1294–1298 (1994).
   PubMed Web of Science ®Google Scholar
• Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. Infect. Dis. 170,1110–1119 (1994).
   Google Scholar
• OHagan D, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 17,2229–2236 (1999).
   Google Scholar
• El-Amad Z, Murthy KK, Higgins K et al. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge with HIV-1SF2. AIDS9, 1313–1322 (1995).
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Lubeck M, Xu S et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. j Viral. 72,1052–1059 (1998).
   PubMed Web of Science ®Google Scholar
• Verschoor EJ, Mooij P, Oostermeijer H et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: evidence for viral clearance. j Viral. 73, 3292–3300 (1999a).
   PubMed Web of Science ®Google Scholar
• Bridges CB, Fukuda K, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 50(RR-4), 1–44 (2001).
   Google Scholar
• Fiebach N, Beckett W Prevention of respiratory infections in adults — influenza and pneumococcal vaccines. Arch. Intern. Med. 154(22), 2545–2557 (1994).
   Google Scholar
• Monto AS. The clinical efficacy of influenza vaccination. Phatmacoeconomics 9(Suppl. 3), 16–22 (1996).
   Google Scholar
• Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA. Influenza in the elderly: report of an outbreak and review of vaccine effectiveness reports. Vaccine 4(1), 38–44 (1986).
   PubMed Web of Science ®Google Scholar
• Keren G, Segev S, Morag A, Zakay-Rones Z, Barzilai A, Rubinstein E. Failure of influenza vaccination in the aged. j Merl Vim'. 25(1), 85–89 (1988).
   PubMedGoogle Scholar
• Phair J, Kauffman CA, Bjornson A, Adams L, Linnemann C Jr. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. j Lab. Clin. Med. 92(5), 822–828 (1978).
   Google Scholar
• Arden NH, Patriarca PA, Lui KJ, Harmon MW, Brandon F, Kendal AR Safety and immunogenicity of a 45-microgram supplemental dose of inactivated split-virus influenza B vaccine in the elderly. j Infect. Dis. 153(4), 805–806 (1986).
   Google Scholar
• Barker WH, Mullooly JR Effectiveness of inactivated influenza vaccine among non-institutionalised elderly persons. In: Options for the Control of Influenza. Kendal AP, Patriarca PA (Eds). Alan R Liss, Inc., NY, USA, 169–182 (1986).
   Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17–19), 2673–2680 (2001).
   Google Scholar
• •Clinical results with the MF59-adjuvanted influenza vaccine.
   Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17(2), 99–104 (1999).
   Google Scholar
• De Donato S, Granoff D, Minutello M et al. A. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17(23–24), 3094–3101 (1999).
   Google Scholar
• Gasparini R, Pozzi T, Montomoli E et al Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur I Epidemiol 17(2), 135–140 (2001).
   Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R, Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19 (25-26), 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biagio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21,1268 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet357(9272), 1937-1943 (2001).
   Google Scholar
• ••MF59-adjuvanted influenza vaccine for aninfluenza pandemic.
   Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Planning for the next influenza pandemic: boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21(15), 1687–1693 (2003).
   Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769–2778 (1999).
   Google Scholar
• •Clinical results with the MF59-adjuvanted HBV vaccine.
   Google Scholar
• Langenberg AGM, Burke RL, Adair SF et al A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Ann. Intern. Med. 122, 889–898 (1995).
   Google Scholar
• Straus SE, Wald A, Kost RG et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. j Infect. Dir. 176,1129-1134 (1997).
   Google Scholar
• Corey L, Langenberg AGM, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. Two randomized controlled trials. JAIVIA 282, 331–340 (1999).
   Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein D-adjuvant vaccine to prevent genital herpes. N Eng I Merl 347(21), 1652–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Pass RP, Duliège AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 180,970–975 (1999).
   PubMed Web of Science ®Google Scholar
• Frey SE, Harrison C, Pass RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J. Infect. Dis. 180,1700–1703 (1999).
   PubMed Web of Science ®Google Scholar
• Wang JB, Adler SP, Hempfling S et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J. Infect. Dis. 174,387–392 (1996).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K et al Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185,686-690 (2002).
   Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, Duliège AM, Adler SR Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect. Dis. 21,133–138 (2002).
   Google Scholar
• Kahn JO, Sinangil F, Baenziger J et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1-5F2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV- infected human volunteers. J. Infect. Dis.170,1288-1291 (1994).
   Google Scholar
• Graham BS, Keefer MC, McElrath J et al Fast PE, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann. Intern. Med. 125,270-279 (1996).
   Google Scholar
• Keefer MC, Graham BS, McElrath MJ et al. Safety and immunogenicity of Env 2–3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retmvir. 12,683-693 (1996).
   Google Scholar
• Nitayaphan S, Khamboonruang C, Sirisophana N et al. AFRIMS-RIHES Vaccine Evaluation Group. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 18,1448–1455 (2000).
   Google Scholar
• Cunningham CK, Warn DW, Kang M et al., Pediatric AIDS Clinical Trials Group 230 Collaborators. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Gun. Infect. Dis. 32,801-807 (2001).
   Google Scholar
• McFarland EJ, Borkowsky W Fenton T eta] Pediatric AIDS Clinical Trials Group 230 Collaborators. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect Dis. 184,1331-1335 (2001).
   Google Scholar
• •Clinical results with the MF59-adjuvanted HIV vaccine in infants and neonates.
   Google Scholar
• Borkowsky W, Wara D, Fenton T et al. Pediatric AIDS Clinical Trials Group 230 Collaborators. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines.j Infect. Dir. 181, 890–896 (2000).
   Google Scholar
• •Clinical results with the MF59-adjuvanted HIV vaccine in infants and neonates.
   Google Scholar